In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo

Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0004. Online ahead of print.ABSTRACTMaurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916.PMID:38437698 | DOI:10.7326/J24-0004

Source: Annals of Internal Medicine - March 4, 2024 Category: Internal Medicine Authors: Ahmad Masri Harriette G C Van Spall Source Type: research